metformin has been researched along with Osteolysis in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-κB Ligand (RANKL)." | 7.91 | Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion. ( Cao, X; Lu, Z; Tian, X; Wei, D; Yan, Z; Ye, Z; Zhai, D; Zhu, Q; Zhu, S; Zhu, Z, 2019) |
| "Metformin could limit the osteolysis induced by implant debris." | 7.88 | Metformin suppresses UHMWPE particle-induced osteolysis in the mouse calvaria by promoting polarization of macrophages to an anti-inflammatory phenotype. ( Cao, X; Liu, Y; Lu, Z; Tian, X; Yan, Z; Yang, C; Yu, L; Zhang, D; Zhu, J; Zhu, Q, 2018) |
| " We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-κB Ligand (RANKL)." | 3.91 | Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion. ( Cao, X; Lu, Z; Tian, X; Wei, D; Yan, Z; Ye, Z; Zhai, D; Zhu, Q; Zhu, S; Zhu, Z, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, Z | 2 |
| Zhu, S | 1 |
| Tian, X | 2 |
| Ye, Z | 1 |
| Zhai, D | 1 |
| Zhu, Z | 1 |
| Wei, D | 1 |
| Zhu, Q | 2 |
| Lu, Z | 2 |
| Cao, X | 2 |
| Zhu, J | 1 |
| Yu, L | 1 |
| Zhang, D | 1 |
| Liu, Y | 1 |
| Yang, C | 1 |
2 other studies available for metformin and Osteolysis
| Article | Year |
|---|---|
Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Bone and Bones; Cell Differentiatio | 2019 |
Metformin suppresses UHMWPE particle-induced osteolysis in the mouse calvaria by promoting polarization of macrophages to an anti-inflammatory phenotype.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Macrophages; Male; Metformin; Mice, Inbred C57BL | 2018 |